Johnson & Johnson’s (JNJ) stock price has fallen approximately 13% since the beginning of the year. However, operating earnings are expected to increase modestly while operating cash flow is expected to increase 45% or more after dropping 1% in 2020 and 9% in 2022.
Nevertheless, JNJ’s dividend is well covered and the company’s balance sheet contains enough cash and short-term investments to cover any contingent liabilities from several lawsuits on talcum powder and opioids.
From a valuation perspective, JNJ has fallen into fair value territory, but we do not consider it dramatically undervalued.
Consequently, for those investors who are looking for high quality, and above-average dividend yield approaching 3%, JNJ may be just the ticket. The point is that the future return is expected to be positive but single digit. Considering the quality of this AAA rated behemoth with a strong balance sheet, it could be attractive to many types of investors.
We consider JNJ a solid hold and a reasonably valued buy at this time. In order to receive a true margin of safety, Johnson & Johnson would have to fall further from here which may or may not occur. Caveat emptor.
FAST Graphs Analyze Out Loud Video
— Chuck Carnevale
Your 12 income checks supercharged with 21% yields [sponsor]Imagine having 12 new monthly income checks, carrying the potential of up to 21% yields.This is possible because of a tested strategy to get paid out regularly, like a paycheck. For over a decade, I have helped more than 26,000 investors secure 12 new monthly payouts. Meaning, you know exactly how much you'll make every month... Because of some stocks that pay us 8%,13.4%, and even 21.6% yields. See it for yourself here.
Source: FAST Graphs